A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC

1. Voluntarily participate in this clinical study, understand study procedures, and be capable of providing written informed consent.
2. Aged ≥18 years at the time of informed consent signature; both male and female subjects are eligible.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Histologically or cytologically confirmed Stage II-III non small cell lung cancer (NSCLC) deemed by the investigator amenable to curative intent R0 surgical resection. Disease staging shall be performed per the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) 9th edition NSCLC staging system.
5. Availability of sufficient tumor tissue specimens.
6. Have measurable target lesions assessed by computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
7. Adequate hematologic and end organ function.
8. Female subjects of child bearing potential who have not undergone surgical sterilization, and male subjects, must agree to use at least one medically accepted contraceptive method during study treatment and for 180 days after the end of study treatment. For non surgically sterilized female subjects of child bearing potential, serum human chorionic gonadotropin (HCG) test must be negative within 14 days prior to the first study drug administration.

Exclusion Criteria:

1. Histologically or cytologically confirmed mixed small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC), large cell neuroendocrine carcinoma, or sarcomatoid carcinoma.
2. Subjects with non squamous NSCLC histology harboring positive epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) positivity.
3. Presence of uncontrolled third space effusions, e.g., substantial pleural effusion, ascites, or pericardial effusion.
4. Prior receipt of any anti neoplastic therapy, including but not limited to radiotherapy, chemotherapy, targeted therapy, immunotherapy, antibody drug conjugates (ADCs), etc.
5. Participation in another clinical study within 4 weeks or 5 half lives of the investigational product (whichever is shorter) prior to the first study drug administration.
6. Receipt of systemic immunosuppressive therapy within 2 weeks before the first study drug administration.
7. Congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection.
8. Active hepatitis B (HBV DNA ≥ 1000 IU/mL), hepatitis C (positive hepatitis C antibody with HCV RNA above the lower limit of quantification of the assay), or co infection with both HBV and HCV.
9. Presence of autoimmune disease. The following conditions are permitted: type 1 diabetes mellitus with glycemic control achievable via insulin therapy; hypothyroidism secondary to autoimmune thyroiditis requiring only hormone replacement therapy; vitiligo limited to cutaneous manifestations (psoriatic arthritis must be excluded).
10. History of other malignancies (other than NSCLC) within 5 years prior to screening, except for adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin carcinoma, radically resected localized prostate cancer, and radically resected ductal carcinoma in situ (hormonal therapy for non metastatic prostate or breast cancer is permitted).
11. Subjects with prior history of interstitial pneumonia requiring corticosteroid therapy.
12. Subjects with severe cardiovascular or cerebrovascular diseases, including arrhythmias judged by the investigator to be clinically significant and markedly abnormal rendering the subject ineligible for trial enrollment.
13. Severe infection occurring within 4 weeks before the first study drug administration; evidence of active tuberculosis infection within 1 year prior to first study drug administration.
14. Subjects with prior or planned allogeneic bone marrow transplantation or solid organ transplantation.
15. History of live attenuated vaccine administration within 28 days before the first study drug administration, or planned administration of live attenuated vaccines during the study period.
16. Arterial or venous thromboembolic events occurring within 3 months.
17. Clinically significant bleeding episodes or evident bleeding diathesis within 1 month prior to the first study drug administration.
18. Pregnant or lactating women; subjects of child bearing potential who are unwilling or unable to implement effective contraceptive measures.
19. Known allergy, hypersensitivity, or intolerance to adebrelimab, chemotherapeutic agents, or their excipients.
20. Known history of psychotropic substance abuse, alcoholism, or illicit drug use.
21. Any condition that, in the investigator's opinion, may jeopardize the subject or prevent the subject from meeting or complying with study requirements.